ZYME cites FDA approval and acquisitions to drive growth
ZYME says a recent FDA approval and commercial launch of zanidatamab in GEA supported growth. It also highlights a strategy combining royalty aggregation, R&D innovation, and acquisitions including Theravance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.